Published in Antimicrob Agents Chemother on February 01, 2005
Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev (2007) 3.43
Global challenge of antibiotic-resistant Treponema pallidum. Antimicrob Agents Chemother (2009) 1.30
Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol (2011) 1.10
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis. Antimicrob Agents Chemother (2014) 0.81
Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. World J Gastroenterol (2014) 0.79
Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol (2012) 0.78
Multiple mutations and increased RNA expression in tetracycline-resistant Streptococcus pneumoniae as determined by genome-wide DNA and mRNA sequencing. J Antimicrob Chemother (2015) 0.77
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
Structure of the 30S ribosomal subunit. Nature (2000) 23.11
Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science (1994) 11.18
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev (2001) 9.14
Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature (1987) 8.96
Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev (2000) 5.21
Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother (1992) 4.82
Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology (1997) 3.04
Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother (1992) 2.86
Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 2.79
Aflagellated mutants of Helicobacter pylori generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis. Mol Microbiol (1993) 2.42
Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther (1997) 2.01
Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol (1996) 1.99
16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother (1998) 1.94
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter (2000) 1.78
Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol (2002) 1.70
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother (2001) 1.68
Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother (1994) 1.62
Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother (2000) 1.44
Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.42
Lymphoma of the gastrointestinal tract. Semin Oncol (1999) 1.41
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter (1999) 1.33
Therapy of Helicobacter pylori: current status and issues. Gastroenterology (2000) 1.32
Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother (2002) 1.27
16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.21
Interaction of tetracycline with RNA: photoincorporation into ribosomal RNA of Escherichia coli. Nucleic Acids Res (1997) 1.20
Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.19
Ribosomal protection from tetracycline mediated by Tet(O): Tet(O) interaction with ribosomes is GTP-dependent. Biol Chem (1998) 1.14
Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol (2003) 1.14
Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.13
DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother (2001) 1.11
The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect (2002) 1.09
Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother (1995) 1.09
High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.09
Helicobacter pylori resistance to tetracycline. Lancet (1996) 0.95
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents (2002) 0.93
Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect (2002) 0.89
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc (2009) 4.76
Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol (2008) 4.44
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Should preoperative chest CT be recommended to all colon cancer patients? Ann Surg (2014) 2.65
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Coexistence between carotid artery stenosis and colorectal adenomatous polyps in middle-aged men. Digestion (2009) 2.02
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol (2010) 1.75
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol (2009) 1.71
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
Is all ineffective esophageal motility the same? A clinical and high-frequency intraluminal US study. Gastrointest Endosc (2008) 1.61
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc (2010) 1.56
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Pathological bolus exposure plays a significant role in eliciting non-cardiac chest pain. J Gastroenterol Hepatol (2010) 1.53
Efficacy and safety of endoscopic treatment for nonampullary sporadic duodenal adenomas. Dig Dis Sci (2013) 1.53
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Am J Gastroenterol (2000) 1.50
Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol (2011) 1.50
Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev (2007) 1.50
Gastrointestinal tract involvement in hepatocellular carcinoma: clinical, radiological and endoscopic studies. Endoscopy (1990) 1.49
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. Korean J Gastroenterol (2009) 1.48
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr (2011) 1.47
Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol (2005) 1.44
Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol (2004) 1.43
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter (2005) 1.42
Comparison of malignant potential between serrated adenomas and traditional adenomas. J Gastroenterol Hepatol (2007) 1.42
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol (2006) 1.41
Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr (2011) 1.40
[Microsatellite instability in gastric B-cell lymphoma]. Korean J Gastroenterol (2006) 1.39
[Predictive factors of response to medical therapy in Crohn's disease patients with intestinal obstruction]. Korean J Gastroenterol (2013) 1.39
Helicobacter pylori infection--a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter (2013) 1.38
Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell (2005) 1.37
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med (2002) 1.35
Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter (2004) 1.35
Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol (2002) 1.34
Efficacy and tolerability of split-dose magnesium citrate: low-volume (2 liters) polyethylene glycol vs. single- or split-dose polyethylene glycol bowel preparation for morning colonoscopy. Am J Gastroenterol (2010) 1.32
Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol (2011) 1.30
Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg (2002) 1.29
Analysis of pacemaker activity in the human stomach. J Physiol (2011) 1.28
Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol (2013) 1.28
Correlation between Helicobacter pylori OipA protein expression and oipA gene switch status. J Clin Microbiol (2004) 1.27
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am (2010) 1.26
Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch). Am J Gastroenterol (2003) 1.25
Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc (2004) 1.23
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2009) 1.22
Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol (2007) 1.22
Helicobacter pylori virulence and cancer pathogenesis. Future Oncol (2014) 1.21
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter (2011) 1.21
Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol (2003) 1.21
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol (2011) 1.20
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol (2012) 1.20
Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology (2002) 1.19
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation. Cell Microbiol (2008) 1.19
vacA i-region subtyping. Gastroenterology (2008) 1.18
Clinical diagnosis of primary epiploic appendagitis: differentiation from acute diverticulitis. J Clin Gastroenterol (2002) 1.17
Diet, lifestyle and gender in gastro-esophageal reflux disease. Dig Dis Sci (2007) 1.16
Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol (2013) 1.15
Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut (2013) 1.14
Role of deletion located between the intermediate and middle regions of the Helicobacter pylori vacA gene in cases of gastroduodenal diseases. J Clin Microbiol (2009) 1.13
Endoscopic mucosal resection of early gastric cancer: Experiences in Korea. World J Gastroenterol (2007) 1.13
Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol (2007) 1.13
Comparison of genotyping Helicobacter pylori directly from biopsy specimens and genotyping from bacterial cultures. J Clin Microbiol (2003) 1.13
Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun (2005) 1.12
Glomus tumor of the stomach: a clinicopathologic analysis of 10 cases and review of the literature. Gut Liver (2012) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci (2008) 1.11
The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver (2011) 1.11
Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med (2005) 1.11
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10